Ibdenc

25/11/2025

Integrating multi-omics data to reveal the host-microbiota interactome in inflammatory bowel disease || New IBD Research Explained || Watch the video to learn more! 🔬

Understanding inflammatory bowel disease (IBD) requires more than studying gut bacteria alone - it demands uncovering the entire interactome between microbes...

22/11/2025

Our Editorial Recommendations of the Month –
🔰To see more: https://www.ibdenc.org/ibd-journalscan
The IBD Emerging Nations’ Consortium (IBD-ENC), presents this month’s top editorial picks from leading global journals!

Dive into groundbreaking insights on the gut microbiome, multi-omics, and host–microbiota interactions in inflammatory bowel disease (IBD). This month’s highlights explore:

- Westernized gut microbiome shifts in Indian immigrants
- Multi-omics and microbiota interplay in IBD
- Bacterial co-abundance patterns in ulcerative colitis
- New perspectives on creeping fat and microbiota in Crohn’s disease
- Oral microbiome’s emerging role in IBD

Each study offers a step forward in understanding the complex interplay between our microbiome and intestinal health.
📚 Explore more at www.ibdenc.org

18/11/2025

How Western Diets Reshape the Gut Microbiome in Indian Immigrants | New IBD Research Explained
Watch the video to learn more! 🔬

The adoption of a westernized gut microbiome in Indian Immigrants and Indo-Canadians is closely linked to dietary acculturation.This video breaks down a rece...

14/11/2025

IBDENC (IBD Emerging Nation's Consortium) in its formal journey of five years now stands at the forefront of IBD research, representing patients from our region. It is time to bring the literature that validates and showcase the regional IBD data speaking for its population.

We are extremely excited to announce the Rise Edition (Inaugural Edition) of the IBDENC Journal in January 2026.

An open access, peer reviewed and most importantly featuring IBD data set that matters for us.

A new beginning in IBD research, education and patient welfare for all across emerging nations.

13/11/2025

💡Our Editorial Recommendations of the Month – November 2025
The IBD Emerging Nations’ Consortium (IBD-ENC), presents this month’s top editorial picks from leading global journals! 🌍

Dive into groundbreaking insights on the gut microbiome, multi-omics, and host–microbiota interactions in inflammatory bowel disease (IBD). This month’s highlights explore:
🔹 Westernized gut microbiome shifts in Indian immigrants
🔹 Multi-omics and microbiota interplay in IBD
🔹 Bacterial co-abundance patterns in ulcerative colitis
🔹 New perspectives on creeping fat and microbiota in Crohn’s disease
🔹 Oral microbiome’s emerging role in IBD

Each study offers a step forward in understanding the complex interplay between our microbiome and intestinal health. 💡
📚 Explore more at www.ibdenc.org

07/11/2025

31/10/2025

This month, our spotlight is on combination therapy - the evolving frontier in IBD management.
From classic benchmarks to cutting-edge dual biologic strategies, these pivotal studies are shaping how we approach treatment in ulcerative colitis (UC) and Crohn’s disease (CD).
Featured Highlights:
🔹SONIC (NEJM) – Infliximab + Azathioprine in CD
🔹UC SUCCESS (Gastroenterology) – Infliximab + Azathioprine in UC
🔹COMMIT (Gastroenterology) – Infliximab + Methotrexate in CD
🔹DIAMOND (JCC) – Adalimumab + Azathioprine in CD
🔹VEGA (The Lancet G&H) – Guselkumab + Golimumab in UC
🔹EXPLORER (CGH) – Vedolizumab + Adalimumab + Methotrexate in CD
🔹VETO (AP&T) – Vedolizumab + Tofacitinib in UC

Together, these landmark trials illustrate the growing importance of synergistic therapies to deepen remission and improve outcomes.

🌐Read more and stay updated: www.ibdenc.org

26/09/2025

⏰ Last chance to register!
Join the AIG IUS Preceptorship in IBD – Nov 3–7, 2025.
Asia’s 1st IUS-Dedicated Center 🌏
Apply before Sept 30 👉 https://forms.office.com/r/uFLBV2HGre